Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its upcoming participation in the Cowen 45th Annual Healthcare Life Sciences Conference. The company will present on Tuesday, March 4 at 11:50 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Events and Presentations section of Adverum's website. A replay will remain available on the site for at least 30 days after the event.
Adverum is working to establish gene therapy as a new standard of care for highly prevalent ocular diseases, positioning this conference appearance as an opportunity for the company to share updates on its clinical progress and pipeline developments.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ADVM gained 9.66%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET.
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the Cowen Healthcare Conference?
How can investors access ADVM's presentation at the Cowen conference?
What is Adverum Biotechnologies' (ADVM) primary focus area?
What stock exchange is ADVM listed on?
Where is Adverum Biotechnologies headquartered?
